Cipher Pharmaceuticals Inc. (TSX:CPH) today announced the Canadian launch of OZANEX™ (ozenoxacin cream, 1%), a novel bactericidal topical antibiotic cream indicated for the treatment of impetigo...

Substantially reduces cost of capital and interest expense, provides additional capacity to support future growth MISSISSAUGA, ON, Nov. 3, 2017 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH)...

Strong Q3 performance 29% revenue growth and 77% growth in income from continuing operations Production resumes at Puerto Rico manufacturing facilities MISSISSAUGA, ON, Nov. 3, 2017 /CNW/ - Cipher...

In the news release, Notice of Cipher Pharmaceuticals Q2 2017 conference call, issued today at 09:32, please note that an error occurred in the headline which should read "Notice of Cipher...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today commented on the impact from Hurricane Maria to its manufacturing partner's facilities in Puerto Rico. Galephar...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today commented on a warning letter issued to Cipher by the Office of Prescription Drug Promotion of the U.S. Food and Drug...

Company achieves important strategic milestones, delivers strong financial results MISSISSAUGA, ON, Aug. 11, 2017 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced the details of its Q2 2017 financial results conference call on Friday, August 11, 2017. Q2 2017 CONFERENCE CALL...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced that Chris Watters has joined the Company in the new position of Vice President, Corporate Development. Mr....

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company"), in accordance with Toronto Stock Exchange requirements, announced the voting results from its Annual Meeting of Shareholders held...